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The placebo is the most commonly-employed
treatment across cultures and throughout history (1).
Today’s physician, resting on her evidence-based
laurels, might have no trouble accepting this claim
when considering the medical practice of yore.After all,
what else can one make of the potions, herbs, leechings
and rituals of our distant colleagues of an earlier age—
medicine men, shamans, wizards—if not that they were,
wittingly or ignorantly, purveyors of placebos? None of
this ought to be relevant to our enlightened time, when
we can exploit our understanding of physiology,
pathology, pharmacology and the double-blind
randomized placebo-controlled study to deliver
scientifically-informed, empirically-validated,
precisely-targeted therapeutic interventions.
Yet the placebo is here, a central item of our
pharmacopeia, widespread and, certainly in the opinion
of most clinicians, effective. This is the clear conclusion
of a series of recent studies whose purpose was to gauge
the extent of placebo use amongst physicians and to
give some sense of how effective practitioners found
them to be. Using decidedly low-tech methods (i.e.
questionnaires), findings across disparate locales were
impressively uniform. For over 500 Danish physicians
who responded to a questionnaire, placebo use was as
high as 86% amongst general practitioners, 54%
amongst hospital-based physicians, and 41% of private
specialists (2). In Chicago, 45% of 231 internists
affiliated with three local medical schools admitted to
using the placebo (3). In our own study in Israel, we
questioned 90 physicians and nurses in primary and
tertiary care and found that 60% used the placebo (4). In
all locales, the placebo was administered in a variety of
forms and for a variety of purposes, and was believed
by most of its purveyors to be ethical and effective.
Some may be surprised by these findings. The local
press even typically reports them (“Israeli Physicians
Give Phony Meds” was one headline that I found
particularly unsavory). Yet it is likely that these reports
actually underestimate the extent of placebo use.
Allow me to justify this statement. The placebo is
notoriously difficult to define (5). Indeed, even the
surveys quoted above did not use a uniform definition.
The Danish survey offered as a definition of placebo an
intervention “not considered to have any ‘specific’
effect on the condition treated, but with a possible
‘unspecific’ effect.” The Chicago questionnaire asked
the physician to define placebo, the three possibilities
including treatment with a non-specific effect (37%), an
intervention not expected to have an effect through a
known physiologic mechanism (51%), or treatment that
is inert or innocuous (28%). The Israeli survey simply
skirted the issue and started asking questions about
placebo use. For all surveys, a placebo could take the
form of vitamins, saline injections, sugar pills,
antibiotics (for non-bacterial infections), and sub-
therapeutic dosages of standard medication.
At the risk of reducing one ambiguity to another, it
might help to think of the placebo as anything causing a
therapeutic reaction, or “placebo effect”, by
psychological means, such as providing reassurance,
assuaging anxiety, eliciting conditioned responses or
arousing positive expectancy. (Some may object that I
have here consigned psychotherapy to the status of a
placebo; but I do not think that is a problem for one who
appreciates the potential of placebo effects and the
many ways of usefully producing them [6]. Ultimately,
psychological effects are as real as any other.)
Thought of in this way, it becomes apparent that the
placebo effect is part of every intervention. The
inscrutable scrawl on the prescription pad, the
reassuring smile, the limp stethoscope hung from the
nape of the neck—these all contribute to the placebo
effect. So, apparently, do the color of the pill (7), and
even the number of pills swallowed by the patient (8,9).
You just can’t avoid the placebo effect (although,
admittedly, comatose patients may be an exception). If
you doubt this, just consider what happens if you
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artificially nullify the placebo effect. This has been
tried, by concealing from the patient that he was
receiving medication. The result was that morphine
calmed pain less, diazepam did not calm anxiety at all,
atropine only slightly increased heart rate, while
propranolol only slightly decreased it (10,11). On the
other hand, revealing that the pill to be provided is a
placebo may not necessarily abolish its benefit (12, 13);
apparently our reaction to treatment and all that it
entails is too deeply conditioned to be reversed by mere
full disclosure.
The placebo is at last being appreciated for its
subversive potential. To ponder the placebo leads one to
reconsider many of our presumptions about the gap
between mind and body, about the untapped subtleties
of medical treatment, and about what really heals when
we administer our therapies.
People are often concerned about the ethics of the
placebo. Certainly, giving a placebo where a more
effective therapeutic alternative is available would be
unethical. Similarly, providing a placebo in the futile
hope of distinguishing “organic” from “supratentorial”
maladies, or simply for the purpose of being done with
an irksome patient, cannot be defended. Yet under
certain circumstances, as I have described elsewhere
(14), the placebo—whether an inert pill, a superfluous
vitamin, or a miniscule, sub-therapeutic dose of
medication—can be legitimately and ethically offered
as treatment. If standard treatments have failed or
caused intolerable side effects, a placebo may
sometimes provide comfort.
Two case vignettes may help illustrate how the
placebo can be usefully and ethically employed. A 62-
year-old man suffering from post-operative pain was
treated with repeated intramuscular injections of an
opioid analgesic, but continued to complain of intense
pain and to demand further injections.The staff, seeking
to avoid an excessive dose, decided to alternate opioid
analgesics with intramuscular saline. They explained to
the patient that saline injections have often been found
to alleviate pain, and they expressed optimism that it
would help him as well. The patient responded well to
the treatment, to everyone’s satisfaction.
A 38-year- old woman in psychotherapy for
depression expressed her belief that her problem was
"chemical", and the talk therapy was pointless. Insisting
that she get "a prescription for a pill", the hesitant
psychiatrist relented and provided 10 mg of imipramine,
a medication that usually requires 100-200 mg and two-
to-four weeks to achieve a therapeutic effect.The doctor
explained that while higher doses are often used, they
would wait to see her reaction to this dose, which can
also be of benefit (15). The woman at her next weekly
visit reported an immediate and significant
improvement. She subsequently decided to leave
psychotherapy, returning every 3-4 months to the
psychiatrist to renew her prescription.
The ethical problem with the placebo, then, is deceit.
The solution, we suggest, is honesty. The physician
must convey to the patient the message that, "Though
we don’t know exactly how this pill works, it can help
you feel better.”
In fact, if we want to be completely frank with our
patients, this sentence might have to accompany just
about any treatment we might offer.
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